Results: FAB

Search articles by EPIC code
EPIC FAB
views

Fusion Antibodies – CEO has now left after little more than a year… and who’s the successor then?

On 21st February Fusion Antibodies (FAB) announced the resignation of CEO Richard Jones, though stating “Richard will remain with the company while arrangements are put in place for his successor. The board has initiated a formal search for a new CEO”. It has today announced that “Richard Jones has now stepped down from his role as CEO, effective from 11 March 2022”. Who’s the successor then?…

EPIC FAB
views

Fusion Antibodies – ‘not aware of reason for share price fall’. Er...

Fusion Antibodies (FAB), “specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, notes the recent movement in the company's share price”. By “recent movement” it means fall from 96p at the start of this month to a last close 82.5p. So what’s the reason?...

EPIC FAB
views

Fusion Antibodies – interims, really “a strong all-round performance” and outlook confidence?

Antibody contract research organisation Fusion Antibodies (FAB) has announced results for its half-year ended 30th September 2021 emphasising “20% underlying growth in revenues over H1 FY2021… and in particular the two major contracts which were secured which, taken together with the remaining pipeline of projects with other customers, give the board confidence that revenues for the full year will be in line with current expectations”. However, what is the financial impact of the revenue and what are the full year expectations?...

Page 1 of 2 (17 articles)
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments